Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CATX

Perspective Therapeutics Inc

Dec 13 • 04:00PM ET

3.48

Dollar change +0.01
Percentage change 0.29	%

Healthcare • Medical Devices • USA • AMEX

Peers: TGTX KPTI AVXL IMUX XOMA CLPT CYCN ONCT KALA MNOV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	27.62%	Shs Outstand	67.56M	Perf Week	-7.45%
Market Cap	235.21M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	1.01%	Shs Float	48.92M	Perf Month	-64.95%
Income	-23.91M	PEG	-	EPS next Q	-0.27	Inst Own	75.59%	Short Float	21.35%	Perf Quarter	-73.48%
Sales	8.84M	P/S	26.61	EPS this Y	53.61%	Inst Trans	25.21%	Short Ratio	6.83	Perf Half Y	-67.48%
Book/sh	4.86	P/B	0.72	EPS next Y	-41.67%	ROA	-27.07%	Short Interest	10.45M	Perf Year	28.32%
Cash/sh	3.96	P/C	0.88	EPS next 5Y	-	ROE	-29.53%	52W Range	2.28 - 19.05	Perf YTD	-13.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-7.69%	ROI	-7.21%	52W High	-81.73%	Beta	1.16
Dividend TTM	-	Quick Ratio	9.60	Sales past 5Y	-	Gross Margin	27.13%	52W Low	52.63%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	9.60	EPS Y/Y TTM	-1350.47%	Oper. Margin	-346.50%	RSI (14)	22.44	Volatility	9.24% 13.93%
Employees	119	Debt/Eq	0.01	Sales Y/Y TTM	-19.63%	Profit Margin	-270.46%	Recom	1.18	Target Price	16.05
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	46.03%	Payout	-	Rel Volume	0.88	Prev Close	3.47
Sales Surprise	26.02%	EPS Surprise	1.59%	Sales Q/Q	-82.33%	Earnings	Nov 12 AMC	Avg Volume	1.53M	Price	3.48
SMA20	-20.89%	SMA50	-61.26%	SMA200	-71.90%	Trades		Volume	1,352,151	Change	0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral	$24 → $5
Oct-24-24	Initiated	UBS	Buy	$20
Oct-01-24	Initiated	Wedbush	Outperform	$25
Sep-25-24	Initiated	Truist	Buy	$21
Jul-25-24	Initiated	BofA Securities	Buy	$24
May-09-24	Initiated	Cantor Fitzgerald	Overweight

Nov-27-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in December (GlobeNewswire) -6.36%
Nov-26-24 07:00AM	Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital (TipRanks) +19.24%
06:45AM	Perspective Therapeutics downgraded to Neutral from Buy at BofA (TipRanks)
Nov-21-24 07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire) -51.38%
07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire)
01:26AM	Loading…
Nov-16-24 01:26AM	Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-15-24 04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire) -11.66% -11.68%
04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire)
Nov-12-24 04:37PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.94%
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results (GlobeNewswire)
Oct-31-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire)
Oct-23-24 07:00AM	Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) -5.65%
Oct-16-24 07:00AM	Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey (GlobeNewswire)
Oct-12-24 10:18AM	Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies (Insider Monkey)
08:30AM	Loading…
Oct-11-24 08:30AM	Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research (GlobeNewswire)
Oct-10-24 05:14PM	Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research (GlobeNewswire)
Oct-07-24 07:00AM	Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day (GlobeNewswire)
Sep-30-24 07:00AM	Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) +6.21%
Sep-10-24 07:00AM	Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024 (GlobeNewswire)
Sep-05-24 07:00AM	Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma (GlobeNewswire)
Aug-28-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 09:40AM	Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year? (Zacks) +5.71%
Aug-12-24 04:35PM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results (GlobeNewswire)
Jul-30-24 07:00AM	Perspective Therapeutics to Participate at Upcoming Investor Conferences in August (GlobeNewswire)
Jul-25-24 06:15AM	3 Outperforming Stocks Surpassing Even Nvidia This Year (InvestorPlace) +6.24%
Jul-22-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet (Zacks)
Jun-12-24 07:00AM	Perspective Therapeutics Announces Inclusion in the Russell 3000 Index (GlobeNewswire) +5.56%
07:00AM	Loading…
Jun-11-24 07:00AM	Perspective Therapeutics Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Jun-10-24 04:10PM	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire) +8.33%
May-24-24 08:01AM	Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-20-24 07:00AM	Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 (GlobeNewswire)
May-15-24 07:49AM	Perspective Therapeutics Swings to Loss in Q1, Revenue Rises (MT Newswires) -10.80%
07:13AM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results (GlobeNewswire)
May-03-24 07:00AM	Perspective Therapeutics to Participate at Upcoming May Investor Conferences (GlobeNewswire)
03:04AM	Lantheus Holdings Inc (LNTH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-02-24 07:00AM	Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 07:00AM	Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-a-NET in NETs (GlobeNewswire)
07:00AM	Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT- -NET in NETs (GlobeNewswire)
Apr-08-24 08:00AM	Perspective Therapeutics to Participate at Upcoming April Investor Conferences (GlobeNewswire)
Mar-30-24 05:31AM	Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
Mar-28-24 07:30AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 10:39AM	Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal (The Wall Street Journal) +16.06%
Mar-18-24 08:00AM	Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma (GlobeNewswire) -9.81%
Mar-11-24 08:00AM	Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility (GlobeNewswire)
Mar-04-24 09:45AM	Perspective Therapeutics Announces $87.4 Million Private Placement (GlobeNewswire) +11.72%
Feb-26-24 08:00AM	Perspective Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) -6.25%
Feb-20-24 06:30AM	These Drug Companies Are Going Nuclear to Fight Cancer (The Wall Street Journal)
Feb-12-24 08:00AM	Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -7.79%
Feb-08-24 10:00AM	Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline (Zacks) -5.72%
Feb-01-24 08:00AM	Perspective Therapeutics Introduces Pre-Targeting Theranostic Technology Platform (GlobeNewswire)
Jan-22-24 04:05PM	Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement (GlobeNewswire)
Jan-18-24 07:00AM	Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement (GlobeNewswire) +26.12%
Jan-17-24 04:05PM	Perspective Therapeutics Announces Proposed Public Offering (GlobeNewswire)
08:00AM	Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT--NET and [(212)Pb]VMT01 (GlobeNewswire)
Jan-09-24 08:00AM	Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability (GlobeNewswire) +9.15%
08:00AM	Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics (GlobeNewswire)
Jan-05-24 08:00AM	Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment (GlobeNewswire) +8.77%
Jan-02-24 08:00AM	Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 08:00AM	Perspective Therapeutics Divests Brachytherapy Business (GlobeNewswire) -5.24%
Dec-07-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT--NET to Treat Refractory or Relapsed Neuroendocrine Tumors (GlobeNewswire)
Nov-28-23 08:00AM	Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT--NET by Clinical Collaborators in Germany (GlobeNewswire)
Nov-27-23 08:00AM	Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals (GlobeNewswire)
Nov-16-23 08:00AM	Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy (GlobeNewswire)
Nov-14-23 04:25PM	Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire) +8.53%
Nov-08-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT--NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors (GlobeNewswire)
Oct-16-23 08:00AM	Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma (GlobeNewswire)
Oct-10-23 08:00AM	Perspective Therapeutics VMT--NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium (GlobeNewswire)
Oct-05-23 04:05PM	Perspective Therapeutics Cesium-131 Featured at the American Society for Radiation Oncologys Annual Conference (GlobeNewswire)
Sep-12-23 08:00AM	Perspective Announces Presentation of Positive Early Clinical Data for VMT--NET at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Sep-11-23 08:00AM	Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-30-23 08:17AM	Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023 (GlobeNewswire)
Aug-28-23 08:00AM	Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-11-23 09:15AM	Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:11AM	Perspective Therapeutics: Q2 Earnings Snapshot (AP Finance)
08:05AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma (GlobeNewswire)
08:00AM	Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire)
Aug-09-23 08:05AM	Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment (GlobeNewswire)
Jun-27-23 08:00AM	Perspective Therapeutics Cesium-131 Featured at the American Brachytherapy Societys Annual Conference (GlobeNewswire)
Jun-21-23 08:00AM	Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates (GlobeNewswire)
Jun-16-23 08:00AM	Perspective Therapeutics Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Societys Annual Meeting (GlobeNewswire) +24.37%
Jun-08-23 08:00AM	Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference (GlobeNewswire)
May-28-23 06:36PM	The Best Penny Stock to Buy Now ZH vs CATX vs LMFA (InvestorPlace)
May-24-23 08:10AM	Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) (GlobeNewswire)
May-16-23 05:02AM	Perspective Therapeutics: Fiscal Q3 Earnings Snapshot (AP Finance) -21.54%
May-15-23 08:22PM	Perspective Therapeutics Reports First Quarter Fiscal 2023 Results (GlobeNewswire)
05:35PM	Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:49PM	Perspective Therapeutics Announces Changes to the Board of Directors (GlobeNewswire)

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENSON HEIDI	Director	Dec 04 '24	Buy	3.85	25,975	100,004	25,975	Dec 06 04:05 PM
Spoor Johan M.	CEO	Dec 04 '24	Buy	3.77	8,000	30,132	36,257	Dec 04 05:20 PM
Williamson Robert F III	Director	Nov 25 '24	Buy	3.64	6,266	22,814	430,058	Nov 27 07:05 AM
Hunt Jonathan Robert	Chief Financial Officer	Nov 25 '24	Buy	3.82	12,829	48,974	48,800	Nov 27 07:00 AM
Spoor Johan M.	CEO	Nov 25 '24	Buy	3.78	14,500	54,868	152,072	Nov 26 07:00 AM
Spoor Johan M.	CEO	Nov 25 '24	Buy	3.80	12,000	45,600	66,600	Nov 26 07:00 AM
Mark Austin	affiliate	Sep 12 '24	Proposed Sale	15.80	2,500	39,500		Sep 12 02:44 PM
Hunt Jonathan Robert	Chief Financial Officer	Jun 17 '24	Buy	9.81	1,800	17,667	35,971	Jun 18 07:48 AM
Woods Lori A	Director	Jun 14 '24	Buy	10.90	4,587	49,990	159,985	Jun 18 07:45 AM
Spoor Johan M.	CEO	Jun 13 '24	Buy	1.17	100,000	117,430	137,572	Jun 13 05:19 PM
Woods Lori A	Director	Jun 03 '24	Buy	1.46	34,246	49,992	1,553,984	Jun 04 04:02 PM
Hunt Jonathan Robert	Chief Financial Officer	May 31 '24	Buy	1.40	25,006	35,007	341,716	Jun 03 04:05 PM
Williamson Robert F III	Director	May 31 '24	Buy	1.38	55,000	75,900	423,792	Jun 03 04:01 PM
Williamson Robert F III	Director	May 29 '24	Buy	1.33	30,031	40,014	368,792	May 30 04:05 PM
Austin Mark John	VP Finance/Prin Fin&Acct Offic	Apr 23 '24	Option Exercise	0.36	30,000	10,800	84,030	Apr 24 04:35 PM
Lantheus Alpha Therapy, LLC	10% Owner	Mar 06 '24	Buy	0.95	60,431,039	57,409,487	116,773,394	Mar 08 11:24 AM
Williamson Robert F III	Director	Jan 30 '24	Buy	0.71	127,206	90,710	338,761	Feb 01 04:53 PM
Williamson Robert F III	Director	Jan 26 '24	Buy	0.56	110,613	62,304	186,289	Jan 30 04:57 PM
Williamson Robert F III	Director	Jan 29 '24	Buy	0.64	25,266	16,170	211,555	Jan 30 04:57 PM
Puhlmann Markus	Chief Medical Officer	Jan 24 '24	Buy	0.50	280,000	139,888	1,375,425	Jan 26 05:40 PM
Williamson Robert F III	Director	Jan 24 '24	Buy	0.49	29,862	14,632	53,542	Jan 26 05:38 PM
Williamson Robert F III	Director	Jan 25 '24	Buy	0.49	22,134	10,846	75,676	Jan 26 05:38 PM
Williamson Robert F III	Director	Dec 21 '23	Buy	0.33	3,663	1,203	3,663	Dec 26 05:00 PM
Hunt Jonathan Robert	Chief Financial Officer	Dec 18 '23	Buy	0.26	125,000	32,338	316,710	Dec 19 07:11 PM
Williamson Robert F III	Director	Dec 19 '23	Buy	0.32	13,680	4,378	23,680	Dec 19 07:10 PM
Williamson Robert F III	Director	Dec 18 '23	Buy	0.26	10,000	2,600	10,000	Dec 19 07:10 PM
Puhlmann Markus	Chief Medical Officer	Dec 19 '23	Buy	0.34	400,000	137,000	1,095,425	Dec 19 07:09 PM
Puhlmann Markus	Chief Medical Officer	Dec 15 '23	Buy	0.27	135,006	36,276	635,006	Dec 19 07:09 PM
Puhlmann Markus	Chief Medical Officer	Dec 18 '23	Buy	0.26	60,419	15,461	695,425	Dec 19 07:09 PM
Woods Lori A	Director	Dec 15 '23	Buy	0.27	152,962	41,284	1,519,738	Dec 18 04:16 PM
Woods Lori A	Director	Dec 14 '23	Buy	0.27	32,238	8,704	1,366,776	Dec 18 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CATX

Perspective Therapeutics Inc

Upgrade your FINVIZ experience